- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- loxooncology.com
- Total Funding
- $57.0M
- Last Round
- $24.0M Series BMay 2014
About
Loxo Oncology was a biopharmaceutical company focused on developing precision oncology medicines targeting cancers driven by specific genetic abnormalities. Its pipeline included larotrectinib (VITRAKVI), the first FDA-approved tumor-agnostic TRK inhibitor. The company was acquired by Eli Lilly in February 2019 for approximately $8 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account